News & Updates

Tofacitinib demonstrates greater efficacy than placebo at week 12 in patients with ankylosing spondylitis (AS) regardless of their baseline C-reactive protein (CRP) levels, a study has shown.

A high mortality risk hounds patients with acute exacerbation (AE) of fibrotic interstitial lung disease (FILD) despite treatment with corticosteroids, reports a study, noting that such risk is similar to that seen in those with AE of idiopathic pulmonary fibrosis (IPF).